1 Dai ZK, "Upregulation of endothelial nitric oxide synthase and endothelin-1 in pulmonary hypertension secondary to heart failure in aorta-banded rats" 37 : 249-256, 2004
2 Prie S, "The orally active ET(A) receptor antagonist (+)-(S)-2-(4,6- dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphe nyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats" 282 : 1312-1318, 1997
3 Galie N, "The endothelin system in pulmonary arterial hypertension" 61 : 227-237, 2004
4 Todd L, "Pulmonary toxicity of monocrotaline differs at critical periods of lung development" 19 : 731-737, 1985
5 Sastry BK, "Pharmacologic treatment for pulmonary arterial hypertension" 21 : 561-568, 2006
6 Weber C, "Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects" 60 : 124-137, 1996
7 Tuder RM, "Pathology of pulmonary hypertension" 28 : 23-42, 2007
8 Hill NS, "Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats" 83 : 1209-1215, 1997
9 Kogler H, "Mechanical load-dependent regulation of gene expression in monocrotaline-induced right ventricular hypertrophy in the rat" 93 : 230-237, 2003
10 Park HK, "Enhanced gene expression of renin-angiotensin system, TGF-beta1, endothelin-1 and nitric oxide synthase in right-ventricular hypertrophy" 43 : 265-273, 2001
1 Dai ZK, "Upregulation of endothelial nitric oxide synthase and endothelin-1 in pulmonary hypertension secondary to heart failure in aorta-banded rats" 37 : 249-256, 2004
2 Prie S, "The orally active ET(A) receptor antagonist (+)-(S)-2-(4,6- dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphe nyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats" 282 : 1312-1318, 1997
3 Galie N, "The endothelin system in pulmonary arterial hypertension" 61 : 227-237, 2004
4 Todd L, "Pulmonary toxicity of monocrotaline differs at critical periods of lung development" 19 : 731-737, 1985
5 Sastry BK, "Pharmacologic treatment for pulmonary arterial hypertension" 21 : 561-568, 2006
6 Weber C, "Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects" 60 : 124-137, 1996
7 Tuder RM, "Pathology of pulmonary hypertension" 28 : 23-42, 2007
8 Hill NS, "Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats" 83 : 1209-1215, 1997
9 Kogler H, "Mechanical load-dependent regulation of gene expression in monocrotaline-induced right ventricular hypertrophy in the rat" 93 : 230-237, 2003
10 Park HK, "Enhanced gene expression of renin-angiotensin system, TGF-beta1, endothelin-1 and nitric oxide synthase in right-ventricular hypertrophy" 43 : 265-273, 2001
11 Dupuis J, "Endothelin-receptor antagonists in pulmonary hypertension" 358 : 1113-1114, 2001
12 Janakidevi K, "Endothelin-1 stimulates DNA synthesis and proliferation of pulmonary artery smooth muscle cells" 263 : C1295-C1301, 1992
13 Chen L, "Endothelin-1 and nitric oxide synthase in short rebound reaction to short exposure to inhaled nitric oxide" 281 : H124-H131, 2001
14 Kim H, "Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension" 15 : 640-648, 2000
15 Lee SH, "Endothelin antagonism in pulmonary arterial hypertension" 26 : 402-408, 2005
16 Budhiraja R, "Endothelial dysfunction in pulmonary hypertension" 109 : 159-165, 2004
17 Dai ZK, "Effects of sildenafil on pulmonary hypertension and levels of ET-1, eNOS, and cGMP in aorta-banded rats" 231 : 942-947, 2006
18 Miyauchi T, "Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension" 73 : 887-897, 1993
19 Morice AH, "Combination therapy with bosentan and phosphodiesterase-5 inhibitor in pulmonary arterial hypertension" 26 : 180-181, 2005
20 Schermuly RT, "Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats" 169 : 39-45, 2004
21 Filep JG, "Characterization of receptors mediating vascular responses to endothelin-1 in the conscious rat" 113 : 845-852, 1994
22 Clozel M, "Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats" 231 : 967-973, 2006
23 Yanagisawa M, "A novel potent vasoconstrictor peptide produced by vascular endothelial cells" 332 : 411-415, 1988
24 Itoh T, "A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats" 169 : 34-38, 2004